The Spanish Medicines and Health Products Agency (AEMPS) has developed criteria to adapt the prescription of sotrovimab due to the pandemic situation and the limited drug stock.

**AIM AND OBJECTIVES**
To describe the patients’ population on treatment with sotrovimab and to assess the adequacy of this prescription according to the criteria established by the AEMPS.

**METHODS AND MATERIALS**
Retrospective observational study analysing all sotrovimab prescriptions in patients with SARS-CoV-2 infection from 01/25/2022 to 08/31/2022.

Prescriptions for sotrovimab were collected and analysed to determine whether they met the criteria and whether they were accepted. Data collected from electronic medical records and processed using Excel2019®.

**RESULTS**

- **VACCINATION STATUS**
  - 84% complete
  - 10% unvaccinated
  - 6% incomplete

- **SEROLOGY**
  - 4% >260 BAU/ml
  - 96% ≤260 BAU/ml

Ten per cent of the applications did not meet the criteria: four of them were not accepted (patients did not belong to any risk group); one was accepted, although it was a well-controlled HIV.

**CONCLUSIONS AND RELEVANCE**
The main profile of patients treated with sotrovimab is men with solid organ transplantation, vaccinated and with negative immunity to SARS-CoV-2. Although the appropriateness of the prescription is high, it is necessary to continue protocolising the use of this drug to ensure its rational use.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**